MRV-MNP / Micron Biomedical - LARVOL DELTA

A measles and rubella vaccine microneedle patch in The Gambia: a phase 1/2, double-blind, double-dummy, randomised, active-controlled, age de-escalation trial. (PubMed, Lancet) - "The safety and immunogenicity data support the accelerated development of the MRV-MNP."

Journal • P1/2 data • Infectious Disease • Measles • Rubella

Measles and Rubella Vaccine Microneedle Patch Phase 1-2 Age De-escalation Trial (clinicaltrials.gov) - P1/2 | N=281 | Completed | Sponsor: Micron Biomedical, Inc | Recruiting ➔ Completed | Trial completion date: Jun 2022 ➔ Dec 2022 | Trial primary completion date: Apr 2022 ➔ Nov 2022

Trial completion • Trial completion date • Trial primary completion date • Infectious Disease

Study protocol for a phase 1/2, single-centre, double-blind, double-dummy, randomized, active-controlled, age de-escalation trial to assess the safety, tolerability and immunogenicity of a measles and rubella vaccine delivered by a microneedle patch in healthy adults (18 to 40 years), measles and rubella vaccine-primed toddlers (15 to 18 months) and measles and rubella vaccine-naïve infants ( (PubMed, Trials) - P1/2 | "This trial will provide the first clinical data on the use of a MNP to deliver the MRV and the first data on the use of MNPs in a paediatric population. It will guide future product development decisions for what may be a key technology for future measles and rubella elimination."

Clinical protocol • Journal • P1/2 data • Infectious Disease • Pain • Pediatrics

Measles and Rubella Vaccine Microneedle Patch Phase 1-2 Age De-escalation Trial (clinicaltrials.gov) - P1/2; N=225; Recruiting; Sponsor: Micron Biomedical, Inc; Not yet recruiting ➔ Recruiting; Trial completion date: Sep 2021 ➔ Jun 2022; Trial primary completion date: Jun 2021 ➔ Apr 2022

Clinical • Enrollment open • Trial completion date • Trial primary completion date • Infectious Disease

Measles and Rubella Vaccine Microneedle Patch Phase 1-2 Age De-escalation Trial (clinicaltrials.gov) - P1/2; N=225; Not yet recruiting; Sponsor: Micron Biomedical, Inc

Clinical • New P1/2 trial • Infectious Disease